Using specific cytotoxics with a targeted mind
- 31 December 2007
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 16, 120-126
- https://doi.org/10.1016/j.breast.2007.07.021
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalProceedings of the National Academy of Sciences, 2005
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005
- Improving patient care through molecular diagnosticsSeminars in Oncology, 2004
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cellsOncogene, 2000
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- The p53 Gene in Breast Cancer: Prognostic Value of Complementary DNA Sequencing Versus ImmunohistochemistryJNCI Journal of the National Cancer Institute, 1996
- Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapyNature Medicine, 1995
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993